Advertisement

Psychopharmacology

, Volume 84, Issue 4, pp 489–495 | Cite as

Evaluation of the levels of free and total amitriptyline and metabolites in the plasma and brain of the rat after long-term administration of doses used in receptor studies

  • P. Baumann
  • J. -M. Gaillard
  • M. Jonzier-Perey
  • C. Gerber
  • C. Bouras
Original Investigations

Abstract

This study was conducted in order to investigate the level of amitriptyline (AT) and its metabolites. Three separate experiments were carried out. In two of these experiments, rats were treated over 7 days with IP doses of AT (10 mg/kg in experiment A and 2×20 mg/kg in experiment C). The rats were sacrificed either 2 (experiment C) or 12h (experiments A and C) after the last dose. In experiment B, rats were sacrificed 2 or 12 h after a single dose of 20 mg/kg AT.

The results of these experiments showed the following: in experiment A only AT was measurable in the brain and in the plasma, in contrast to experiments B and C, where NT and the hydroxylated metabolites AT-OH and NT-OH reached significant levels in the plasma and in the brain. The concentrations of AT-OH, NT-OH, and NT (12-h values) that were found in the brain are probably not pharmacologically relevant. The 12-h plasma values of all compounds tested were, even with the highest dose, lower than those expected to be clinically effective in man.

Our results suggest that AT, at higher doses, may induce its own metabolism. The free plasma levels of this drug and its metabolites are higher in man than in the rat.

The possible implications of these results in the use of antidepressants in the treatment of depression are discussed.

Key words

Amitriptyline Hydroxylated metabolites Free drug in plasma Brain Plasma Long-term treatment Kinetics 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Antelman SM, Chiodo LA (1981) Dopamine autoreceptor subsensitivity: a mechanism common to the treatment of depression and the induction of amphetamine psychosis. Biol Psychiatr 16:717–727Google Scholar
  2. Antelman SM, DeGiovanni LA, Kocan D, Perel JM, Chiodo LA (1983) Amitriptyline sensitization of a serotonin-mediated behavior depends on the passage of time and not repeated treatment. Life Sci 33:1727–1730Google Scholar
  3. Baumann P, Koeb L, Tinguely D, Rivier L (1982) A method for the analysis of free, total plasma and saliva amitriptyline and nortriptyline by dialysis and gc/ms. Eur J Mass Spec Biochem Med Environ Res 2:19–26Google Scholar
  4. Baumann P, Tinguely D, Schöpf J, Koeb L, Perey M, Michel L, Balant A, Dick B (1983a) The fate of amitriptyline and its metabolites, taking into account their binding in plasma. In: Gram LF, Usdin E, Dahl SG, Kragh-Sorensen P, Sjöqvist F, Morselli PL (eds) Clinical pharmacology in psychiatry: bridging the experimental-therapeutic gap. Macmillan, London, pp 227–237Google Scholar
  5. Baumann P, Gaillard JM, Perey M, Justafre JC, Le P (1983b) Relationships between brain concentrations of desipramine and paradoxical sleep inhibition in the rat. J Neural Transm 56:105–116Google Scholar
  6. Baumann P, Dick B, Koeb L, Perey M, Schöpf J, Tringuely D (1984) Amitriptyline-Metabolismus im depressiven Patienten: Pharmakogenetische Aspekte und Eiweißbindung im Plasma. In: Hopf A, Beckmann H (eds) Forschungen zur Biologischen Psychiatrie. Springer, Berlin, pp 298–305Google Scholar
  7. Bertilsson L, Mellström B, Sjöqvist F (1979) Pronounced inhibition of noradrenaline uptake by 10-hydroxy-metabolites of nortriptyline. Life Sci 25:1285–1292Google Scholar
  8. Breyer U (1972) Perazine, chlorpromazine and imipramine as inducers of microsomal drug metabolism. Naunyn-Schmiedebergs Arch Pharmacol 272:277–288Google Scholar
  9. Breyer-Pfaff U, Gaertner HJ, Kreuter F, Scharek G, Brinkschulte M, Wiatr R (1982) Antidepressive effect and pharmacokinetics of amitriptyline with consideration of unbound drug and 10-hydroxynortriptyline plasma levels. Psychopharmacology 76:240–244Google Scholar
  10. Cassano GB, Sjöstrand SE, Hansson E (1965a) Distribution of C14-labelled amitriptyline in the cat brain. Psychopharmacology 8:12–22Google Scholar
  11. Cassano GB, Sjöstrand SE, Hansson E (1965b) Distribution and fate of C14-amitriptyline in mice and rats. Psychopharmacology 8:1–11Google Scholar
  12. Charney DS, Heninger GR, Sternberg DE (1983) Alpha-2 adrenergie receptor sensitivity and the mechanism of action of antidrepressant therapy. The effect of long-term amitriptyline treatment. Br J Psychiatr 142:265–275Google Scholar
  13. Chiodo LA, Antelman SM (1980) Tricyclic antidepressants induce subsensitivity of presynaptic dopamine autoreceptors. Eur J Pharmacol 64:203–204Google Scholar
  14. Clements-Jewery S, Robson PA (1982) Intact 5HT neuroterminals are not required for 5HT2 receptor down-regulation by amitriptyline. Neuropharmacology 21:725–727Google Scholar
  15. Daniel W, Adamus A, Melzacka M, Szymura J, Vetulani J (1981) Cerebral pharmacokinetics of imipramine in rats after single and multiple dosages. Naunyn-Schmiedebergs Arch Pharmacol 317:209–213Google Scholar
  16. Delini-Stula A, Vassout A (1979) Modulation of dopamine-mediated behavioural responses by antidepressants: effects of single and repeated treatment. Eur J Pharmacol 58:443–451Google Scholar
  17. De Montigny C, Aghajanian GK (1978) Tricyclic antidepressants: long-term treatment increases responsivity of rat forebrain neurons to serotonin. Science 202:1303–1306Google Scholar
  18. Dumbrille-Ross A, Tang SW, Coscina DV (1982) Lack of effect of raphe lesions on serotonin S2 receptor changes induced by amitriptyline and desmethylimipramine. Psychiatr Res 7:145–151Google Scholar
  19. Edelbroek PM, Zitman FG, Schreuder JN, Rooymans HGM, de Wolff FA (1984) Amitriptyline metabolism in relation to antidepressive effect. Clin Pharmacol Ther 35:467–473Google Scholar
  20. Eschenhof E von, Rieder J (1969) Untersuchungen über das Schicksal des Antidepressivums Amitriptylin im Organismus der Ratte und des Menschen. Arzneim Forsch 19:957–966Google Scholar
  21. Friedman E, Cooper TB (1983) Pharmacokinetics of chlorimipramine and its demethylated metabolite in blood and brain regions of rats treated acutely and chronically with chlorimipramine. J Pharmacol Exp Ther 225:387–390Google Scholar
  22. Garland WA, Muccino RR, Min BH, Cupano J, Fann WE (1979) A method for the determination of amitriptyline and its metabolites nortriptyline, 10-hydroxyamitriptyline, and 10-hydroxynortriptyline in human plasma using stable isotope dilution and gas chromatography-chemical ionization mass spectrometry (GC-CIMS). Clin Pharmacol Ther 25:844–855Google Scholar
  23. Glotzbach RK, Preskorn SH (1982) Brain concentrations of tricyclic antidepressants: single-dose kinetics and relationship to plasma concentrations in chronically dosed rats. Psychopharmacology 78:25–27Google Scholar
  24. Gram LF, Kragh-Sorensen P (1981) Pharmacokinetics and plasma level/effect relationships of tricyclic antidepressants: an update. In: Usdin E, Dahl SG, Gram LF, Lingjaerde O (eds) Clinical pharmacology in psychiatry. Macmillan, London, pp 241–251Google Scholar
  25. Hurst HE, Jarboe CH (1981) Clinical findings, elimination pharmacokinetics, and tissue drug concentrations following a fatal amitriptyline intoxication. Clin Toxicol 18:119–125Google Scholar
  26. Hyttel J, Christensen AV, Fjalland B (1980) Neuropharmacologyical properties of amitriptyline, nortriptyline and their metabolites. Acta Pharmacol Toxicol 47:53–57Google Scholar
  27. Jørgensen A, Hansen V (1976) Pharmacokinetics of amitriptyline infused intravenously in man. Eur J Clin Pharmacol 10:337–341Google Scholar
  28. Jørgensen A, Staehr P (1976) On the biological half-life of amitriptyline. J Pharm Pharmacol 28:62–64Google Scholar
  29. Keller HH, Burkard WP, Da Prada M (1980) Dopamine receptor blockade in rat brain after acute and subchronic treatment with tricyclic antidepressants. In: Cattabeni et al. (eds) Long-term effects of neuroleptics. Adv Biochem Psychopharmacol 24:175–179Google Scholar
  30. Lehman JP, Fenselau C, Depaulo JR (1983) Quaternary ammonium-linked glucuronides of amitriptyline, imipramine, and chloropromazine. Drug Metab Dispos 11:221–225Google Scholar
  31. Maître L, Moser P, Baumann PA, Waldmeier PC (1980) Amine uptake inhibitors: criteria of selectivity. In: Svensson TH, Carlsson A (eds) Biogenic amines and affective disorders. Proc. Symp. London, 18–21 Jan. 1979. Acta Psychiatr Scand (Suppl 61) 280:97–110Google Scholar
  32. Menkes DB, Kehne JH, Gallager DW, Aghajanian GK, Davis M (1983a) Functional supersensitivity of CNS al-adrenoreceptors following chronic antidepressant treatment. Life Sci 33:181–188Google Scholar
  33. Menkes DB, Rasenick MM, Wheeler MA, Bitensky MW (1983b) Guanosine triphosphate activation of brain adenylate cyclase: enhancement by long-term antidepressant treatment. Science 219:65–67Google Scholar
  34. Mishra R, Sulser F (1978) Role of serotonin reuptake inhibition in the development of subsensitivity of the norepinephrine (NE) receptor coupled adenylate cyclase system. Psychopharmacology 2:365–370Google Scholar
  35. Montgomery SA (1981) Prediction of plasma levels and clinical response in depression. In: Usdin E, Dahl SG, Gram LF, Lingjaerde O (eds) Clinical pharmacology in psychiatry. Macmillan, London, pp 263–271Google Scholar
  36. Nobrega JN, Coscina DV (1983) Chronic amitriptyline potentiates feeding induced by intrahypothalamic norepinephrine injections. Life Sci 33:1249–1253Google Scholar
  37. O'Malley K, Browning M, Stevenson I, Turnbull MJ (1973) Stimulation of drug metabolism in man by tricyclic antidepressants. Eur J Clin Pharmacol 6:102–103Google Scholar
  38. Peroutka SJ, Snyder SH (1980a) Long-term antidepressant treatment decreases spiroperidol-labeled serotonin receptor binding. Science 210:88–90Google Scholar
  39. Peroutka SJ, Snyder SH (1980b) Regulation of serotonin 2 (5-HT2) receptors labeled with (3H) spiroperidol by chronic treatment with the antidepressant amitriptyline. J Pharmacol Exp Ther 215:582–587Google Scholar
  40. Potter WZ, Muscettola G, Goodwin FK (1979a) Binding of imipramine to plasma protein and to brain tissue: relationship to CSF tricyclic levels in man. Psychopharmacology 63:187–192Google Scholar
  41. Potter WZ, Calil HM, Manian AA, Zavadil AP, Goodwin FK (1979b) Hydroxylated metabolites of tricyclic antidepressants: preclinical assessment of activity. Biol Psychiatr 14:601–613Google Scholar
  42. Preskorn SH, Hartman BK, Clark HB (1980) Long-term antidepressant treatment: alterations in cerebral capillary permeability. Psychopharmacology 70:1–4Google Scholar
  43. Preskorn SH, Glotzbach RK (1982) A liquid chromatographic method for quantitating amitriptyline in brain tissue. Psychopharmacology 78:23–24Google Scholar
  44. Robinson DS, Cooper TB, Ravaris CL, Ives JO, Nies A, Bartlett D, Lamborn KR (1979) Plasma tricyclic drug levels in amitriptyline-treated depressed patients. Psychopharmacology 63:223–231Google Scholar
  45. Roffman M, Kling MA, Cassens G, Orsulak PJ, Reigle TG, Schildkraut JJ (1977) The effects of acute and chronic administration of tricyclic antidepressants on MHPG-SO4 in rat brain. Psychopharmacol Commun 1:195–206Google Scholar
  46. Schneider G, Schneider G, Bickel MH (1969) Über das Auftreten von Desmethylimipramin im Gehirn der Ratte nach Gabe von Imipramin in Abhängigkeit von der Injektionsart. Psychopharmacology 16:156–160Google Scholar
  47. Schulz P, Turner-Tamiyasu K, Smith G, Giacomini KM, Blaschke TF (1983) Amitriptyline disposition in young and elderly normal men. Clin Pharmacol Ther 33:360–366Google Scholar
  48. Segawa T, Mizuta T, Normura Y (1979) Modification of central 5-hydroxytryptamine binding sites in synaptic membranes from rat brain after long-term administration of tricyclic antidepressants. Eur J Pharmacol 58:75–83Google Scholar
  49. Sellinger-Barnette MM, Mendels J, Frazer A (1980) The effect of psychoactive drugs on beta-adrenergic receptor binding sites in rat brain. Neuropharmacology 19:447–454Google Scholar
  50. Serra G, Argiolas A, Klimek V, Fadda F, Gessa GL (1979) Chronic treatment with antidepressants prevents the inhibitory effect of small doses of apomorphine on dopamine synthesis and motor activity. Life Sci 25:415–424Google Scholar
  51. Tang SW, Helmeste DM, Stancer HC (1978) The effect of acute and chronic desipramine and amitriptyline treatment on rat brain total 3-methoxy-4-hydroxyphenylglycol. Naunyn-Schmiedebergs Arch Pharmacol 305:207–211Google Scholar
  52. Taylor JE, El-Fakanany E, Richelson ER (1979) Long-term regulation of muscarinic acetylcholine receptors on cultured nerve cells. Life Sci 25:2181–2187Google Scholar
  53. Vetulani J, Sulser F (1975) Action of various antidepressant treatments reduces reactivity of noradrenergic cyclic AMP-generating system in limbic forebrain. Nature 257:495–496Google Scholar

Copyright information

© Springer-Verlag 1984

Authors and Affiliations

  • P. Baumann
    • 1
  • J. -M. Gaillard
    • 2
  • M. Jonzier-Perey
    • 1
  • C. Gerber
    • 1
  • C. Bouras
    • 2
  1. 1.Clinique PsychiatriqueUniversitaire de LausannePrilly-LausanneSwitzerland
  2. 2.Clinique PsychiatriqueUniversitaire de Bel-AirChêne-Bourg/GenèveSwitzerland

Personalised recommendations